-
Indiegogo Founder: Netflix Is 'Impressive' And 'Incredible,' Won't Bet Against Hastings
Monday, March 16, 2015 - 3:38pm | 392Read More...Netflix, Inc. (NASDAQ: NFLX) shares slumped by almost 4 percent Monday on back of the stock being downgraded by analysts at Evercore ISI to Sell. However, a lot of people don't agree with the downgrade. Among them is Slava Rubin, co-founder and CEO of Indiegogo. Rubin was on CNBC to...
-
Why Evercore Thinks Netflix Will Drop 13%
Monday, March 16, 2015 - 10:01am | 162Read More...Evercore ISI said that Netflix, Inc.'s (NASDAQ: NFLX) 26 percent gains this year are overdone as the analysts downgraded the company from Hold to Sell and slashed its price target by $70 to $380. Netflix recently traded at $435.41, down 3 percent for the day. Evercore said that the "...
-
NXP Semiconductors Now Worth $130, Evercore Says
Wednesday, March 4, 2015 - 6:13pm | 319Read More...In a report published Wednesday, Evercore ISI analysts maintained a Buy rating on NXP Semiconductors NV (NASDAQ: NXPI), while raising the price target from $90 to $130. In the report, Evercore ISI noted, "NXPI's acquisition of FSL takes us back a couple years where NXPI offered many levers for...
-
What Evercore Is Watching At BioMarin Pharmaceutical
Wednesday, February 25, 2015 - 6:17pm | 221Read More...In a report published Wednesday, Evercore ISI analyst Mark Schoenebaum discussed the latest developments at BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). In the report, Deutsche Bank noted, "BMRN just reported 4Q and FY14 results, as well as 2015 guidance. ~20% top-line beat in the 4Q was driven...
-
The Catalysts Biogen Idec Investors Should Watch
Tuesday, February 24, 2015 - 7:32pm | 143Read More...In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for Biogen Idec Inc (NASDAQ: BIIB). These include: Quarterly calls: Tecfidera sales number March 2015 - ADPD Conference: BIIB-037 Ph 1b mild / prodromal alzheimer's detailed...
-
Catalysts AbbVie Investors Need To Watch
Tuesday, February 24, 2015 - 7:28pm | 180Read More...In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for AbbVie Inc (NASDAQ: ABBV). These include: Quarterly calls - Viekira Pak sales in Hep C Mid-April 2015 - Phase 2b 12-week RA data JAK1 GLPG0634 1H15 - ABT-199 Phase 2 data...
-
The Zoetis Catalyst Schedule Wall Street Is Watching
Tuesday, February 24, 2015 - 7:23pm | 189Read More...In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for Zoetis Inc. (NYSE: ZTS). These include: June 25, 2015 - Tax matters agreement with Pfizer expires. ZTS gets more flexibility in selling itself / doing large scale M&A or...
-
4 Pictures Every Valeant-Salix Investor Should See
Monday, February 23, 2015 - 7:59pm | 335Read More...Canada's Valeant Pharmaceuticals International Inc (NYSE: VRX) has agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd (NASDAQ: SLXP) in an all-cash deal valued at about $10.1 billion. Valeant will pay $158.00 a share for the merger, which is expected to more than $500...
-
Evercore ISI Technical Analysis: The 'Single Best Idea'
Monday, February 23, 2015 - 8:34am | 248Read More...The technical analysts at Evercore ISI are bullish on biotechnology, noting that the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) is in a long-term bull market, not a bubble. So it’s no surprise that the analysts “single best idea” is Biogen Idec Inc (NASDAQ: BIIB)....
-
Gilead Sciences Earnings Preview: Hepatitis C Guidance Is Key
Tuesday, February 3, 2015 - 3:13pm | 287Read More...Gilead Sciences, Inc. (NASDAQ: GILD), expected to post results after the bell Tuesday, remains a darling on Wall Street after fears of a price war for its Sovaldi hepatitis C treatment receded last month. Investors will be looking for the company's estimate of sales related to hepatitis C...
-
Evercore ISI Upgrades Yahoo! To Buy
Friday, January 30, 2015 - 9:18am | 57Read More...Evercore ISI upgraded Yahoo! Inc. (NASDAQ: YHOO) from Hold to Buy. The price target for Yahoo! has been lowered from $59.00 to $55.00. Yahoo! shares have gained 21.44% over the past 52 weeks, while the S&P 500 index has surged 13.39% in the same period. Yahoo! shares rose 0.16% to $43.80 in pre...
-
US Stock Futures Dip Ahead Of GDP Data
Friday, January 30, 2015 - 8:24am | 455Read More...Pre-open movers US stock futures traded lower in early pre-market trade, ahead of earnings from several companies. Data on GDP growth and the employment cost index for the fourth quarter will be released at 8:30 a.m. ET. The Chicago PMI for January will be released at 9:45 a.m. ET, while the...
-
Evercore ISI Upgrades Laboratory Corp. of America To Buy
Tuesday, January 20, 2015 - 8:35am | 72Read More...Analysts at Evercore ISI upgraded Laboratory Corp. of America Holdings (NYSE: LH) from Hold to Buy. The price target for Laboratory Corp. of America has been raised from $105 to $132. Laboratory Corp. of America shares have surged 28.23% over the past 52 weeks, while the S&P 500 index has...
-
Evercore ISI Upgrades Groupon To Hold
Thursday, January 15, 2015 - 8:47am | 59Read More...Analysts at Evercore ISI upgraded Groupon, Inc. (NASDAQ: GRPN) from Sell to Hold. The price target for Groupon has been raised from $6.50 to $8. Groupon shares have dropped 32.88% over the past 52 weeks, while the S&P 500 index has gained 8.96% in the same period. Groupon's shares rose 1.76...
-
US Stock Futures Tumble; Citigroup Earnings In Focus
Thursday, January 15, 2015 - 8:24am | 490Read More...Pre-open movers US stock futures traded lower in early pre-market trade, ahead of earnings from Citigroup Inc. (NYSE: C). Data on weekly jobless claims, the producer price index for December and the Empire State manufacturing index for January will be released at 8:30 a.m. ET. The general...
